Open Access
ARTICLE
Ya-Sian Chang*†‡§, Chieh-Min Chang†‡, Chien-Yu Lin¶#, Dy-San Chao†, Hsi-Yuan Huang†, Jan-Gowth Chang*†‡**††
Oncology Research, Vol.28, No.2, pp. 107-116, 2020, DOI:10.3727/096504019X15698362825407
Abstract The genomic landscape of breast cancer (BC) is complex. The purpose of this study was to decipher the mutational profiles of Taiwanese patients with BC using next-generation sequencing. We performed whole-exome
sequencing on DNA from 24 tumor tissue specimens from BC patients. Sanger sequencing was used to validate the identified variants. Sanger sequencing was also performed on paired adjacent nontumor tissues. After
genotype calling and algorithmic annotations, we identified 49 deleterious variants in canonical cancer-related
genes in our BC cohort. The most frequently mutated genes were PIK3CA (16.67%), FKBP9 (12.5%), TP53
(12.5%), ATM (8.33%), CHEK2 (8.33%), FOXO3 (8.33%), NTRK1… More >
Open Access
ARTICLE
Xiuhua Weng*1, Shaohong Luo*1, Shen Lin*, Lixian Zhong†, Meiyue Li*, Rao Xin*, Pinfang Huang*, Xiongwei Xu*
Oncology Research, Vol.28, No.2, pp. 117-125, 2020, DOI:10.3727/096504019X15707883083132
Abstract To evaluate the cost–utility of pembrolizumab versus chemotherapy as the first-line setting for metastatic nonsmall cell lung cancer (NSCLC) from the US health care system perspective, a Markov model was developed
to compare the lifetime cost and effectiveness of pembrolizumab versus chemotherapy for untreated metastatic NSCLC, based on the clinical data derived from phase III randomized controlled trial (KEYNOTE-
042; ClinicalTrials.gov; NCT02220894). Weibull distribution was fitted to simulate the parametric survival
functions. Drug costs were collected from official websites, and utility values were obtained from published literature. Total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios
(ICERs) were computed… More >
Open Access
ARTICLE
Jianping Xu, Xiaoyan Liu, Sheng Yang, Yuankai Shi
Oncology Research, Vol.28, No.2, pp. 127-133, 2020, DOI:10.3727/096504019X15707896762251
Abstract Apatinib, an oral small molecular receptor tyrosine kinase inhibitor (TKI) developed first in China, exerts antiangiogenic and antineoplastic function through selectively binding and inhibiting vascular endothelial growth
factor receptor 2 (VEGFR-2). In this study, we aimed to explore the efficacy and safety profile of apatinib
monotherapy, or combined with chemotherapy or endothelial growth factor receptor (EGFR)-TKI in heavily
pretreated non-small cell lung cancer (NSCLC) patients with brain metastases. We performed a retrospective
analysis for relapsed NSCLC patients with brain metastases from our institute, who received apatinib
(250 mg or 500 mg p.o. qd) monotherapy, or combination with EGFR-TKI or chemotherapy… More >
Open Access
ARTICLE WITHDRAWN
Lu, Xiaoqin1, Wang, Fuying1, Fu, Meizhou2, Li, Yuankun1, Wang, Lijun1
Oncology Research, Vol.28, No.2, pp. 135-146, 2020, DOI:10.3727/096504019X15719983040135
Abstract This article was wihdrawn by the authors with the following Withdrawal Statement - The integrity of the current study is not acceptable. The authors intend to enrich the study to make it more valuable. Thus, the authors want to withdraw the current study. Please accept our apologies for this inconvenience and we hope for your understanding. Yours sincerely (on behalf of the authors), Xiaoqin Lu. More >
Open Access
ARTICLE
ZiJun Liao*†, Qi Zheng†, Ting Wei‡, YanBing Zhang†, JieQun Ma†, Zheng Zhao§,
HaiFeng Sun§, KeJun Nan*
Oncology Research, Vol.28, No.2, pp. 147-159, 2020, DOI:10.3727/096504019X15732109856009
Abstract MicroRNAs (miRNAs) play crucial roles in tumorigenesis and tumor progression. miR-561 has been reported
to be downregulated in gastric cancer and affects cancer cell proliferation and metastasis. However, the role and
underlying molecular mechanism of miR-561 in human non-small cell lung cancer (NSCLC) remain unknown
and need to be further elucidated. In this study, we discovered that miR-561 expression was downregulated
in human NSCLC tissues and cell lines. The overexpression of miR-561 inhibited NSCLC cell proliferation
and cell cycle G1
/S transition and induced apoptosis. The inhibition of miR-561 facilitated cell proliferation
and G1
/S transition and suppressed apoptosis. miR-561… More >
Open Access
ARTICLE
Nahathai Dukaew*†, Teruaki Konishi‡§, Kongthawat Chairatvit¶, Narongchai Autsavapromporn#,
Noppamas Soonthornchareonnon**, Ariyaphong Wongnoppavich†
Oncology Research, Vol.28, No.2, pp. 161-175, 2020, DOI:10.3727/096504019X15736439848765
Abstract Radiotherapy (RT) is an important treatment for non-small cell lung cancer (NSCLC). However, the major
obstacles to successful RT include the low radiosensitivity of cancer cells and the restricted radiation dose,
which is given without damaging normal tissues. Therefore, the sensitizer that increases RT efficacy without
dose escalation will be beneficial for NSCLC treatment. Eurycomalactone (ECL), an active quassinoid isolated
from Eurycoma longifolia Jack, has been demonstrated to possess anticancer activity. In this study, we aimed
to investigate the effect of ECL on sensitizing NSCLC cells to X-radiation (X-ray) as well as the underlying
mechanisms. The results showed that ECL… More >
Open Access
ARTICLE
Majed Al Fayi*†, Ahmad Alamri*, Prasanna Rajagopalan*†
Oncology Research, Vol.28, No.2, pp. 177-189, 2020, DOI:10.3727/096504019X15746768080428
Abstract Drug discovery research to fight lung cancer is incessantly challenged by drug resistance. In this study, we
used drug-resistant lung cancer stem like cells (A549-CS) to compare the efficacy of standard drugs like cisplatin (DDP) and gemcitabine (GEM) with a novel arylidene derivative IOX-101. A549-CS was derived from
regular A549 cells by growing in special media. Resistance proteins were detected using Western blotting. Cell
proliferations were assessed by MTT assay. Cytokine release was enumerated using enzyme-linked immunosorbent assay. The effect of drugs on apoptosis and cell cycle was studied with flow cytometry protocols.
Apoptosis-related proteins, caspases, and other signaling protein… More >
Open Access
ARTICLE
Daniela D’Angelo*, Claudio Arra†, Alfredo Fusco*
Oncology Research, Vol.28, No.2, pp. 191-201, 2020, DOI:10.3727/096504019X15761465603129
Abstract Long noncoding RNAs have been recently demonstrated to have an important role in fundamental biological processes, and their deregulated expression has been found in several human neoplasias. Our group has
recently reported a drastic overexpression of the long noncoding RNA (lncRNA) RPSAP52 (ribosomal protein SA pseudogene 52) in pituitary adenomas. We have shown that this lncRNA increased cell proliferation
by upregulating the expression of the chromatinic proteins HMGA1 and HMGA2, functioning as a competing endogenous RNA (ceRNA) through competitively binding to microRNA-15a (miR-15a), miR-15b, and
miR-16. The aim of this work was to identify further mechanisms by which RPSAP52 overexpression… More >
Open Access
ARTICLE
Yong Wang*, Rui-Zhi Jia*, Shu Diao*, Jun He†, Li Jia†
Oncology Research, Vol.28, No.2, pp. 203-212, 2020, DOI:10.3727/096504019X15761480623959
Abstract Despite the considerable knowledge on the involvement of microRNA-101 (miR-101) in the evolution of oral
squamous cell carcinoma (OSCC), the underlying mechanisms remain obscure. In this study, miR-101 expression
was markedly downregulated in the OSCC cell lines and tissues. Cell counting kit-8 (CCK-8), ethynyl deoxyuridine (EdU), and colony formation assays showed that miR-101 inhibited the proliferation of OSCC cells. Flow
cytometry and caspase 3 activity assays indicated that miR-101 induced OSCC cell apoptosis. Transwell assays
demonstrated that this miRNA also repressed OSCC cell migration and invasion. Moreover, tube formation
assay showed that miR-101 abated the proangiogenesis of OSCC cells. Dual-luciferase… More >
Login
Register
Submit a Paper
Propose a Special lssue